BioCryst Pharmaceuticals, Inc.
Durham
NC
27703
United States
567 articles about BioCryst Pharmaceuticals, Inc.
-
U.S. Government Exercises Option to Purchase Additional RAPIVAB® (peramivir injection) from BioCryst for Pandemic Influenza Preparedness
8/25/2022
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the U.S. Department of Health and Human Services (HHS) has exercised its option to purchase an additional 10,000 doses of BioCryst’s antiviral influenza therapy, RAPIVAB® (peramivir injection), for approximately $7 million.
-
BioCryst Announces Approval of ORLADEYO® (berotralstat) in Saudi Arabia
8/18/2022
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Saudi Food and Drug Authority (SFDA) has approved oral, once-daily ORLADEYO ® (berotralstat) to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years of age and older in Saudi Arabia.
-
BioCryst to Report Second Quarter 2022 Financial Results on August 4
7/21/2022
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2022 financial results Thursday, August 4, 2022.
-
BioCryst Announces ORLADEYO® (berotralstat) Data to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2022
6/22/2022
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced multiple upcoming data presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2022 from July 1-3, 2022, at the O2 universum in Prague, Czech Republic.
-
BioCryst Selects Pint Pharma as Commercial Partner for ORLADEYO® (berotralstat) in Latin America
6/9/2022
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the company has entered into an exclusive collaboration with Pint Pharma GmbH to register and promote ORLADEYO® (berotralstat) in the pan-Latin America (LATAM) region.
-
FDA Grants Fast Track Designation for BioCryst’s ALK-2 Inhibitor, BCX9250
6/8/2022
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for BCX9250 for the prevention of heterotopic ossification (HO) in patients with fibrodysplasia ossificans progressiva (FOP).
-
BioCryst Announces Approval of ORLADEYO® (berotralstat) by Swissmedic
6/7/2022
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Swissmedic has granted marketing authorization for oral, once-daily ORLADEYO® (berotralstat) for the routine prevention of recurrent hereditary angioedema (HAE) attacks in patients 12 years and older in Switzerland.
-
BioCryst Announces Health Canada has Authorized ORLADEYO® (berotralstat), the Only Oral Treatment for the Prevention of Hereditary Angioedema Attacks
6/6/2022
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Health Canada has approved oral, once-daily ORLADEYO® (berotralstat) for the routine prevention of recurrent hereditary angioedema (HAE) attacks in patients 12 years and older.
-
BioCryst to Present at Upcoming Investor Conferences - June 01, 2022
6/1/2022
BioCryst Pharmaceuticals, Inc. announced that the company will present at the Jefferies Healthcare Conference in New York, NY on Wednesday, June 8, 2022, at 9:00 a.m. ET and the JMP Securities Life Sciences Conference in New York, NY on Wednesday, June 15, 2022, at 12:00 p.m. ET.
-
Pfizer's Paxlovid racks up a rare trial miss, Medicago and GSK publish positive data for their plant-based particle vaccine and Rhythm Pharmaceuticals touts strong potential in Bardet-Biedl Syndrome.
-
BioCryst to Present at Upcoming Investor Conferences - May 06, 2022
5/6/2022
BioCryst Pharmaceuticals, Inc. announced that the company will present at the following conferences:.
-
BioCryst's success of its Orladeyo launch in its Q1 report was overshadowed by the news that the FDA had placed a partial clinical hold on three of its clinical trials evaluating BCX9930
-
BioCryst Reports First Quarter 2022 Financial Results and Upcoming Key Milestones
5/5/2022
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the first quarter ended March 31, 2022, and provided a corporate update.
-
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 04, 2022
5/4/2022
BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted 23 newly-hired employees stock options to purchase an aggregate of 138,100 shares, and restricted stock units covering an aggregate of 69,050 shares, of BioCryst common stock.
-
European Medicines Agency Grants PRIME Designation to BioCryst’s ALK-2 Inhibitor, BCX9250, for Treatment of Fibrodysplasia Ossificans ProgressivaBCX9250 is first investigational drug for FOP to be eligible for program
4/27/2022
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the European Medicines Agency (EMA) has granted access to the Priority Medicines (PRIME) scheme for BCX9250, a novel, oral activin receptor-like kinase-2 (ALK-2) inhibitor discovered and developed by BioCryst for the treatment of fibrodysplasia ossificans progressiva (FOP).
-
BioCryst to Report First Quarter 2022 Financial Results on May 5
4/21/2022
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2022 financial results Thursday, May 5, 2022.
-
The trial demonstrated a safety profile in the younger age group as seen in patients 12 and older, with no severe side effects and no one dropping out from adverse events.
-
BioCryst to Present at Upcoming Investor Conference
4/11/2022
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 21st Annual Needham Virtual Healthcare Conference on Thursday, April 14, 2022, at 11:45 a.m. ET.
-
BioCryst Pauses Enrollment in BCX9930 Clinical Trials
4/8/2022
BioCryst Pharmaceuticals, Inc. announced that the company has paused enrollment in clinical trials with BCX9930 while the company investigates elevated serum creatinine levels seen in some patients.
-
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 05, 2022
4/5/2022
BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted 19 newly-hired employees stock options to purchase an aggregate of 124,800 shares, and restricted stock units covering an aggregate of 47,400 shares, of BioCryst common stock.